Structure of Nalfurafine hydrochloride CAS 152658-17-8

Nalfurafine hydrochloride CAS 152658-17-8

/in , , /by

Identification
Properties
Safety Data
Specifications & Other Information
Links

Identification

CAS Number

152658-17-8

Name

Nalfurafine hydrochloride

Synonyms

(2E)-N-[(5α,6β)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]-3-(3-furyl)-N-methylacrylamide hydrochloride (1:1) [ACD/IUPAC Name]
(2E)-N-[(5α,6β)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]-3-(3-furyl)-N-methylacrylamidhydrochlorid (1:1) [German] [ACD/IUPAC Name]
(2E)-N-[(5α,6β)-17-(Cyclopropylméthyl)-3,14-dihydroxy-4,5-époxymorphinane-6-yl]-3-(3-furyl)-N-méthylacrylamide, chlorhydrate (1:1) [French] [ACD/IUPAC Name]
152658-17-8 [RN]
2-Propenamide, N-[(5α,6β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, (2E)-, hydrochloride (1:1) [ACD/Index Name]
Nalfurafine hydrochloride [USAN]
Nalfurafine (hydrochloride)
Remitch hydrochloride
TRK-820 hydrochloride
UNII-25CC4N0P8J

Molecular Structure

Structure of Nalfurafine hydrochloride CAS 152658-17-8

Structure of Nalfurafine hydrochloride CAS 152658-17-8

SMILES

CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7.Cl

StdInChI

InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1

StdInChIKey

DJSFYNINGIMKAG-FQJQBBMWSA-N

Molecular Formula

C28H33ClN2O5

Molecular Weight

513.025

Properties

Appearance

White powder

Specifications and Other Information of Our Nalfurafine hydrochloride CAS 152658-17-8

Standard

Enterprise standard

Identification Methods

HNMR/HPLC

Purity

98%min

Heavy Metal

10ppm

Storage

Under the room temperature and away from light

Application

Nalfurafine hydrochloride was launched on March of 2009 in Japan as the first in class non-narcotic opioid drug for intractable itch caused by hemodialysis. It showed significant opioid agonist acti vity and induced neither aversion nor preference in rats on the CPP (Conditioned Place Preference) test. A new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients.

Links

This product is developed by our sub R&D company Caming Pharmaceutical Ltd, and please click the link below for details.
http://www.caming.com/nalfurafine-hydrochloride-cas-152658-17-8/

This product is sold exclusively through our sales company Watson International Ltd, and please click the link below for details.
http://www.watson-int.com/nalfurafine-hydrochloride-cas-152658-17-8/